Fluvastatin structure
|
Common Name | Fluvastatin | ||
---|---|---|---|---|
CAS Number | 93957-54-1 | Molecular Weight | 411.466 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 681.8±55.0 °C at 760 mmHg | |
Molecular Formula | C24H26FNO4 | Melting Point | 194-197ºC | |
MSDS | N/A | Flash Point | 366.1±31.5 °C |
Use of FluvastatinFluvastatin (Leschol) inhibits HMG-CoA reductase activity with IC50 of 8 nM.IC50 value: 8 nMTarget: HMG-CoA reductaseFluvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Human hepatocellular carcinoma cell (HCC) studies indicate that Fluvastatin induces G2/M phase arrest. In the presence of Fluvastatin, HCC cells show a decrease of Bcl-2 and procaspase-9 expression, and an increase in Bax, cleaved caspase-3, and cytochrome c. Fluvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. |
Name | Fluvastatin |
---|---|
Synonym | More Synonyms |
Description | Fluvastatin (Leschol) inhibits HMG-CoA reductase activity with IC50 of 8 nM.IC50 value: 8 nMTarget: HMG-CoA reductaseFluvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Human hepatocellular carcinoma cell (HCC) studies indicate that Fluvastatin induces G2/M phase arrest. In the presence of Fluvastatin, HCC cells show a decrease of Bcl-2 and procaspase-9 expression, and an increase in Bax, cleaved caspase-3, and cytochrome c. Fluvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. |
---|---|
Related Catalog | |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 681.8±55.0 °C at 760 mmHg |
Melting Point | 194-197ºC |
Molecular Formula | C24H26FNO4 |
Molecular Weight | 411.466 |
Flash Point | 366.1±31.5 °C |
Exact Mass | 411.184601 |
PSA | 82.69000 |
LogP | 3.62 |
Vapour Pressure | 0.0±2.2 mmHg at 25°C |
Index of Refraction | 1.587 |
Storage condition | 2-8℃ |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Hazard Codes | Xi |
---|---|
Risk Phrases | R36/37/38:Irritating to eyes, respiratory system and skin . R42/43:May cause sensitization by inhalation and skin contact . |
Safety Phrases | S23-S26-S37 |
RIDADR | UN 3272 3/PG 3 |
WGK Germany | 3 |
Packaging Group | III |
Hazard Class | 3 |
~% Fluvastatin CAS#:93957-54-1 |
Literature: US2005/261354 A1, ; Page/Page column 53 ; US 20050261354 A1 |
Precursor 1 | |
---|---|
DownStream 1 | |
(3S,5R,6E)-7-[3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid |
UNII:4L066368AS |
fluvastatin |
6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)- |
FLUVASTATIN NA |
Lipaxan |
MFCD00929076 |
(3R,5S,6E)-7-[3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid |
(3R,5S,6E)-7-[3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid |
Lescol |
(3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid |
(3S,5R,6E)-7-[3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid |
(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid |
(±)-(3R*,5S*,6E)-7-[3-(p-fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptenoate |
6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3S,5R,6E)- |
FLUVASTATIN SODIUM |
Primexin |